In one aspect, there is provided the use of oxaliplatin in the manufacture of a medicament for the treatment of bladder cancer, wherein the medicament is to be locally administered into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue.

CLAIMS

I claim:

1. Use of ~~A medicament comprising~~ oxaliplatin in the manufacture of a medicament for ~~use in~~ the treatment of bladder cancer, wherein the medicament is to be ~~by~~ locally administered~~ing oxaliplatin~~ into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue.

2. The ~~medicament~~ use of claim 1, wherein the medicament is to be locally administered~~ing~~ into the patient's bladder ~~is~~ continuously.

3. The ~~medicament~~ use of claim 1, wherein the medicament is to be locally ~~administering~~ administered into the patient's bladder ~~is~~ intermittently.

4. The ~~medicament~~ use of claim 1, wherein the medicament is to be locally administered~~ing~~ into the patient's bladder ~~is~~ continuously over a period of at least 2 hours.

5. The ~~medicament~~ use of claim 1, wherein the medicament is to be locally administered~~ing~~ into the patient's bladder ~~is~~ at a mean average amount of from 1 mg to about 100 mg oxaliplatin per day for 1 day to 14 days.

6. The ~~medicament~~ use of claim 1, wherein the medicament is to be locally administered~~ing~~ into the patient's bladder ~~is~~ at a mean average amount of from 1 mg to about 100 mg oxaliplatin per day for up to 7 days.

7. The ~~medicament~~ use of claim 1, wherein the ~~oxaliplatin is delivered~~medicament is to be administered into the bladder from an intravesical drug delivery device which continuously releases the ~~oxaliplatin~~ medicament into the urine in the bladder over a sustained period.

8. The ~~medicament~~ use of claim 7, wherein the intravesical drug delivery device continuously releases the ~~oxaliplatin~~ medicament into the urine in the bladder over a period of at least 2 hours.

9. The ~~medicament~~ use of claim 7, wherein the intravesical drug delivery device continuously releases the ~~oxaliplatin~~ medicament into the urine in the bladder over a period of 1 day to 14 days.

10. The ~~medicament~~ use of any one of claims 7 to 9, wherein the intravesical drug delivery device comprises a housing which contains and controllably releases the ~~oxaliplatin~~ medicament and is elastically deformable between a retention shape configured to retain the device in a patient's bladder and a deployment shape for passage of the device through the patient's urethra.

11. The ~~medicament~~ use of claim 10, wherein the ~~oxaliplatin contained in the housing~~medicament is in a non-liquid form.

12. The ~~medicament~~ use of claim 11, wherein the non-liquid form is selected from the group consisting of tablets, granules, semisolids, capsules, and combinations thereof.

13. The ~~medicament~~ use of claim 1, wherein the ~~oxaliplatin~~ medicament is to be delivered into the bladder from a coating substance to be applied to the bladder, which coating substance continuously releases the ~~oxaliplatin~~ medicament into the urine in the bladder over a sustained period.

14. The ~~medicament~~ use of claim 13, wherein the coating substance comprises a mucoadhesive formulation.

15. The ~~medicament~~ use of claim 1, wherein the locally administer~~ed~~ing comprises pumping a liquid form of the medicament~~oxaliplatin~~ into the bladder through a urethral catheter which is deployed into the bladder.

16. A drug delivery device comprising a medicament according to any one of the preceding claims, configured to release oxaliplatin when the drug delivery device is inserted into the bladder.

~~17. A method of administering oxaliplatin to a patient in need of treatment of bladder cancer, the method comprising:~~

~~locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue.~~

~~18~~17. The ~~method~~ use of claim ~~17~~, wherein ~~further comprising administering~~ at least a second therapeutic agent is to be administered to the patient.

~~19~~18. The ~~method~~ use of claim ~~18~~17, wherein the second therapeutic agent is to be administered intravesically.

~~20~~19. The ~~method~~ use of claim ~~18~~ 17 or ~~19~~18, wherein the second therapeutic agent comprises gemcitabine or another cytotoxic agent; an analgesic agent; an anti-inflammatory agent; or a combination thereof.

~~21~~20. A medical device comprising:

a housing configured for intravesical insertion; and

a dosage form comprising oxaliplatin,

wherein the housing holds the dosage form and is configured to release the oxaliplatin into the bladder in amount therapeutically effective for the treatment of prostate cancer.

~~22~~21. The device of claim ~~21~~20, which is configured to release from 1 mg/day to 100 mg/day of oxaliplatin for up to 7 days.